App aims to boost breast cancer treatment adherence
NCT ID NCT06905301
First seen Feb 05, 2026 · Last updated May 03, 2026 · Updated 12 times
Summary
This study looks at whether using a mobile app helps people with HR+ HER2- stage II or III breast cancer stick to their prescribed ribociclib and aromatase inhibitor therapy for a full year. The app provides reminders and information about side effects and relapse risks. About 240 participants will be split into two groups: one using the app and one not, and researchers will compare how many in each group stay on treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGPskov, Russia, 180000, Russia
-
Novartis Investigative Site
RECRUITINGMoscow, 115304, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194017, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194291, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 197758, Russia
-
Novartis Investigative Site
RECRUITINGUfa, 450054, Russia
Conditions
Explore the condition pages connected to this study.